Search Results - "Bossuyt, V."

Immunological differences between primary and metastatic breast cancer by Szekely, B., Bossuyt, V., Li, X., Wali, V.B., Patwardhan, G.A., Frederick, C., Silber, A., Park, T., Harigopal, M., Pelekanou, V., Zhang, M., Yan, Q., Rimm, D.L., Bianchini, G., Hatzis, C., Pusztai, L.

“…Little is known about how the immune microenvironment of breast cancer evolves during disease progression. We compared tumor infiltrating lymphocyte (TIL)…”
Get full text

Recommendations for standardized pathological characterization of residual disease for neoadjuvant clinical trials of breast cancer by the BIG-NABCG collaboration by Bossuyt, V., Provenzano, E., Symmans, W.F., Boughey, J.C., Coles, C., Curigliano, G., Dixon, J.M., Esserman, L.J., Fastner, G., Kuehn, T., Peintinger, F., von Minckwitz, G., White, J., Yang, W., Badve, S., Denkert, C., MacGrogan, G., Penault-Llorca, F., Viale, G., Cameron, D., Earl, Helena, Alba, Emilio, Lluch, Ana, Albanell, Joan, Amos, Keith, Biernat, Wojciech, Bonnefoi, Hervé, Buzdar, Aman, Cane, Paul, Pinder, Sarah, Carson, Lesley, Dickson-Witmer, Diana, Gong, Gyungyub, Green, Jimmy, Hsu, Chih-Yi, Tseng, Ling-Ming, Kroep, Judith, Leitch, A. Marilyn, Sarode, Venetia, Mamounas, Eleftherios, Marcom, Paul Kelly, Nuciforo, Paolo, Paik, Soonmyung, Peg, Vicente, Peston, David, Pierga, Jean-Yves, Quintela-Fandino, Miguel, Salgado, Roberto, Sikov, William, Thomas, Jeremy, Unzeitig, Gary, Wesseling, Jelle

“…Neoadjuvant systemic therapy (NAST) provides the unique opportunity to assess response to treatment after months rather than years of follow-up. However,…”
Get full text

Comparison of 2 Serum-Free Light-Chain Assays in CKD Patients by Sprangers, Ben, Claes, Kathleen, Evenepoel, Pieter, Kuypers, Dirk, Poesen, Koen, Delforge, Michel, Bossuyt V, Xavier, Meijers, Björn

“…Quantification of serum-free light chains (FLCs) is important in the diagnosis and monitoring of paraprotein-related diseases. There are currently 2 FLC assays…”
Get full text

A novel UBE3A sequence variant identified in eight related individuals with neurodevelopmental delay, results in a phenotype which does not match the clinical criteria of Angelman syndrome by Geerts‐Haages, Amber, Bossuyt, Stijn N. V., Besten, Inge, Bruggenwirth, Hennie, Burgt, Ineke, Yntema, Helger G., Punt, A. Mattijs, Brooks, Alice, Elgersma, Ype, Distel, Ben, Valstar, Marlies

“…Background Loss of functional UBE3A, an E3 protein ubiquitin ligase, causes Angelman syndrome (AS), a neurodevelopmental disorder characterized by severe…”
Get full text

Loss of nuclear UBE3A causes electrophysiological and behavioral deficits in mice and is associated with Angelman syndrome by Avagliano Trezza, Rossella, Sonzogni, Monica, Bossuyt, Stijn N. V., Zampeta, F. Isabella, Punt, A. Mattijs, van den Berg, Marlene, Rotaru, Diana C., Koene, Linda M. C., Munshi, Shashini T., Stedehouder, Jeffrey, Kros, Johan M., Williams, Mark, Heussler, Helen, de Vrij, Femke M. S., Mientjes, Edwin J., van Woerden, Geeske M., Kushner, Steven A., Distel, Ben, Elgersma, Ype

“…Mutations affecting the gene encoding the ubiquitin ligase UBE3A cause Angelman syndrome. Although most studies focus on the synaptic function of UBE3A, we…”
Get full text

Loss of nuclear UBE3A activity is the predominant cause of Angelman syndrome in individuals carrying UBE3A missense mutations by Bossuyt, Stijn N V, Punt, A Mattijs, de Graaf, Ilona J, van den Burg, Janny, Williams, Mark G, Heussler, Helen, Elgersma, Ype, Distel, Ben

“…Abstract Angelman syndrome (AS) is a severe neurodevelopmental disorder caused by deletion (~75%) or mutation (~10%) of the ubiquitin E3 ligase A (UBE3A) gene,…”
Get full text

Remarkably High Frequency of EGFR Expression in Breast Carcinomas with Squamous Differentiation by Bossuyt, V., Fadare, O., Martel, M., Ocal, I. T., Burtness, B., Moinfar, F., Leibl, S., Tavassoli, F. A.

“…The human epidermal growth factor receptor (EGFR) is reportedly overexpressed in 15-20% of breast carcinomas. EGFR overexpression is associated with reduced…”
Get full text

Early detection of cytotoxic events between hepatic natural killer cells and colon carcinoma cells as probed with the atomic force microscope by Braet, F., Vermijlen, D., Bossuyt, V., De Zanger, R., Wisse, E.

“…The atomic force microscope (AFM) is a powerful tool to investigate surface and submembranous structures of living cells under physiological conditions at high…”
Get full text

Abstract PD6-02: Immunological differences between primary and metastatic breast cancer by Szekely, B, Bossuyt, V, Li, X, Baine, M, Silber, A, Sanft, T, Hofstatter, E, Mougalian, S, Baghwagar, S, Neumeister, V, Pelekanou, V, Hatzis, C, Pusztai, L

“…Abstract Background: Little is known about how the immune microenvironment of breast cancer evolves during disease progression. Immunological differences…”
Get full text

Abstract P2-04-02: Comparison of DNA methylation patterns in normal breast tissue from women with and without breast cancer by Hofstatter, EW, Zhu, Y, Horvath, S, Chagpar, AB, Wali, VB, Bossuyt, V, Storniolo, AM, Hatzis, C, Patwardhan, G, Von Wahlde, M-K, Butler, M, Epstein, L, Stavris, K, Sturrock, T, Au, A, Kwei, S, Pusztai, L

“…Abstract BACKGROUND: Increasing evidence suggests that epigenetic mechanisms play critical roles in the development of breast cancer. However, precise DNA…”
Get full text

Effect of fungal biomass in alfalfa hay on intake and total tract digestion in growing beef calves by Bossuyt, C.V. (University of Manitoba, Winnipeg, MB, Canada.), Wittenberg, K.M, Crow, G.H

“…Two experiments were conducted to determine effects of fungal biomass (FB) as determined by glucosamine analysis, in alfalfa hay on intake and total tract…”
Get full text

Abstract P3-13-01: Impact of routine cavity shave margins on time and money: Results from the SHAVE trial by Chagpar, AB, Longley, PB, Horowitz, NR, Killelea, BK, Tsangaris, TN, Li, F, Butler, M, Stavris, K, Yao, X, Harigopal, M, Bossuyt, V, Lannin, DR, Pusztai, L, Loftus, M, Davidoff, AJ, Gross, CP

“…Abstract INTRODUCTION: Taking routine cavity shave margins (CSM) reduces positive margin and re-excision rates by 50%, but the impact of this technique on…”
Get full text

P3-05-08: Hormone Receptor Heterogeneity in Ductal Intraepithelial Neoplasia (Ductal Carcinoma In Situ) of the Breast by Sowden, M, Flynn, C, Bossuyt, V, Lannin, D, Chagpar, AB

“…Abstract Background: Ductal Intraepithelial Neoplasia [DIN] often shows heterogeneity of both morphology and nuclear grade within the same patient. It is…”
Get full text

Abstract PD05-05: RNA-seq identifies unique transcriptomic changes after brief exposure to preoperative nab-paclitaxel (N), bevacizumab (B) or trastuzumab (T) and reveals down-regulation of TGF-β signaling associated with response to bevacizumab by Varadan, V, Kamalakaran, S, Janevski, A, Banerjee, N, Lezon-Geyda, K, Miskimen, K, Bossuyt, V, Abu-Khalaf, M, Sikov, W, Dimitrova, N, Harris, LN

“…Abstract Background: Identification of differentially expressed transcripts upon brief exposure to preoperative therapy can help determine likely response…”
Get full text

Abstract P3-14-01: Molecular definition of the transition of ductal carcinoma in situ (DCIS) to invasive ductal carcinoma (IDC) by Colavito, S, Stepansky, A, Madan, A, Harris, LN, Hicks, J, Bossuyt, V, Rimm, D, Lannin, D, Stern, DF

“…Abstract Background: Ductal carcinoma in situ (DCIS) is thought to be a precursor lesion to invasive ductal carcinoma and sometimes occurs in combination with…”
Get full text

Abstract P4-01-02: Association of DCE-MRI texture features with molecular phenotypes and neoadjuvant therapy response in breast cancer by Banerjee, N, Maity, S, Varadan, V, Janevski, A, Kamalakaran, S, Sikov, W, Abu-Khalaf, M, Bossuyt, V, Lannin, D, Harris, L, Cornfeld, D, Dimitrova, N

“…Abstract Purpose: MRI imaging phenotype features such as volume and morphology are used to characterize tumor heterogeneity and tumor response. Texture-based…”
Get full text

Quantitative assessments and clinical outcomes in HER2 equivocal 2018 ASCO/CAP ISH group 4 breast cancer by Gupta, Swati, Neumeister, Veronique, McGuire, John, Song, Yan S., Acs, Balazs, Ho, Kenneth, Weidler, Jodi, Wong, Wendy, Rhees, Brian, Bates, Michael, Rimm, David L., Bossuyt, Veerle

“…We quantified human epidermal growth factor receptor 2 (HER2) RNA and protein expression in 2018 American Society of Clinical Oncology/College of American…”
Get full text

P1-06-23: Changes in Gene Expression after One Dose of Trastuzumab (T) in HER2+ Breast Cancer Cell Lines Predict Novel Pathways of Response in HER2 Positive Early Stage Breast Cancer by Sprecher, E, Lezon-Geyda, K, Sarkar, S, Bossuyt, V, Narayaan, M, Kumar, A, Krop, I, Winer, E, Tuck, D, Kleinstein, S, Harris, L

“…Abstract Introduction: Trastuzumab is a targeted therapy against the HER2 cell surface receptor and has greatly improved prognosis for HER2+ breast cancer…”
Get full text

P3-06-01: Next Generation RNA Sequencing Reveals Changes in Gene Expression and Alternative Splicing upon Brief Exposure to Therapy in Early Breast Cancer by Varadan, V, Kamalakaran, S, Janevski, A, Banerjee, N, Lezon-Geyda, K, Bossuyt, V, Flowers, D, Sikov, W, Abu-Khalaf, M, Rizack, T, Dimitrova, N, Harris, LN

“…Abstract Background The use of next generation RNA sequencing (RNA-seq) allows for the characterization of the transcriptome at levels of detail unachievable…”
Get full text

P3-06-04: Sno/miRNA Expression Via Next Generation Sequencing: Variation in Patients before and after Treatment by Banerjee, N, Kamalakaran, S, Varadan, V, Janevski, A, Lezon-Geyda, K, Bossuyt, V, Flowers, D, Sikov, W, Abu-Khalaf, M, Rizack, T, Harris, L, Dimitrova, N

“…Abstract Background Aberrant expression of small RNA molecules has been shown in breast cancer. It is yet unclear if variation exists in small RNA molecule…”
Get full text